The Society for Cardiovascular Angiography and Interventions (SCAI) has named Lisa Olson, PhD, as its new executive director. Olson brings deep experience and expertise in the cardiovascular field and a vision for continuing to advance SCAI’s mission.

Amaranth Medical, a privately held medical device company, announced the initiation of patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and feasibility of the Company's FORTITUDE(R) Sirolimus-Eluting Bioresorbable Scaffold in patients with symptomatic coronary artery disease. As seen with the first generation scaffold, preliminary patient results using optical coherence tomography (OCT) following implantation show that the scaffolds were fully apposed to the vessel wall achieving optimal acute lumen gain.

Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic, Inc. augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for peripheral artery disease (PAD) in leg arteries above the knee.

New data from the Boston Scientific clinical trial program of the Lotus Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement.

The Spectranetics Corporation today announced that Eric Dippel, MD, at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, presented findings from the EXCITE ISR clinical trial proving Spectranetics' laser atherectomy devices, used with PTA (also known as balloon angioplasty), are clinically superior to PTA alone in both safety and efficacy, triggering a new standard in cardiovascular care. 

Drug-eluting balloons rather than drug-eluting stents may have a place in certain clinical scenarios, cardiologists said Sept. 14 during a press conference at the Transcatheter Cardiovascular Therapeutics scientific session.

Google Glass one day could become an interventional cardiologist’s new best friend, based on a demonstration Sept. 15 at the Transcatheter Cardiovascular Therapeutics scientific session that showed how the technology was used during a transradial PCI.

Six weeks of triple therapy to provide anticoagulation to patients treated with drug-eluting stents was not superior to six months, according to results of the ISAR-TRIPLE trial presented Sept. 15 at the Transcatheter Cardiovascular Therapeutics scientific session. Panelists suggested sample size was a problem.